Drug Trial Radar · NCT01796301
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
436
Actual
Start
Jan 31, 2013
Primary completion
May 14, 2015
Study completion May 14, 2015
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 55 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.
Conditions
- Postmenopausal Osteoporosis
Interventions
RomozosumabDrug
Administered by subcutaneous injection once a month.
TeriparatideDrug
Administered by subcutaneous injection once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)Time frame: Baseline, month 6 and month 12
Locations
50 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Gainesville, Georgia
Research Site
Bethesda, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Córdoba, Córdoba Province, Argentina
Research Site
Genk, Belgium
Research Site
Ghent, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Calgary, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Medellín, Antioquia, Colombia
Research Site
Barranquilla, Atlántico, Colombia
Research Site
Brno, Czechia
Research Site
Ostrava, Czechia
Research Site
Pilsen, Czechia
Research Site
Praha 11 - Chodov, Czechia
Research Site
Uherské Hradiště, Czechia
Research Site
Aalborg, Denmark
Research Site
Aarhus C, Denmark
Research Site
Ballerup Municipality, Denmark
Research Site
Esbjerg, Denmark
Research Site
Hillerød, Denmark
Research Site
Hvidovre, Denmark
Research Site
Odense, Denmark
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Gdynia, Poland
Research Site
Katowice, Poland
Research Site
Warsaw, Poland
Research Site
Wroclaw, Poland
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.